-+ 0.00%
-+ 0.00%
-+ 0.00%

Benchmark Reiterates Speculative Buy on Anebulo Pharmaceuticals, Maintains $8 Price Target

Benzinga·10/01/2024 11:54:51
Listen to the news
Benchmark analyst Robert Wasserman reiterates Anebulo Pharmaceuticals (NASDAQ:ANEB) with a Speculative Buy and maintains $8 price target.